FDA meetings are not just regulatory milestones, they are one of the most reliable mechanisms available to de‑risk your development program, align your evidence plan, and avoid expensive missteps and rework. However, in our experience, many sponsors, including early stage companies, show up to these meetings with broad questions, unclear objectives, or with a briefing package that does not set FDA up to give usable feedback.
In this article, we share high-level practical guidance to help:
- Select the most appropriate FDA meeting format based on program status and objectives (e.g., INTERACT, pre‑IND, Type D, etc.)
- Frame focused questions that will yield clear, actionable FDA feedback
- Develop a briefing package that tells a cohesive, compelling story for your investigational product and supports your rationale
- Manage Agency touchpoints end-to-end
For companies developing drugs, biologics, or medical devices, interactions with the FDA represent some of the most pivotal moments in the product development lifecycle. In today’s rapidly evolving biopharma landscape, early interactions with the FDA can be the difference between accelerated success and costly setbacks. These meetings should be initiated as early as feasible since the Agency’s feedback helps shape development pathways, clarify regulatory expectations, reduce program risk, and create positive signals for investors.
For early-stage companies, FDA interactions can be especially high value. When done right, they can de-risk key development decisions, sharpen your evidence plan, and create confidence with investors well before major spend. In many cases, it is worth considering an INTERACT meeting for novel or complex programs that would benefit from very early Agency input, or a pre-IND (Type B) meeting when you’re ready to pressure-test your proposed clinical trial design. However, Sponsors need to think through their strategy carefully. For instance, FDA does not always grant INTERACT requests, so it is important to evaluate whether INTERACT or pre-IND is the best fit for your specific questions and timing. And because you typically only get one shot at a pre-IND meeting, it is important that you make it count by aligning the right objectives, asking focused questions, and submitting a high-quality package that sets you up for clear, actionable feedback.
Yet many organizations underutilize these opportunities or enter them without the preparation needed to fully leverage the Agency’s insight. Sponsors that achieve the greatest success are those that treat FDA engagements not as procedural checkpoints, but as strategic inflection points that can accelerate development, reduce risk, and increase the probability of future approval.
Below are key strategies to ensure your organization makes the most of every FDA interaction.
1. Choose the Right Meeting at the Right Time
The FDA offers multiple meeting types tailored to the stage and needs of your program:
- INTERACT: Very early engagement for novel or complex programs
- Type A: Clinical hold discussions, dispute resolution, special protocol assessment follow-up
- Type B: Milestone Meetings ( Pre-IND, pre-NDA/BLA)
- Type B (End Of Phase Meeting): Certain end-of-phase 1 meetings and end of Phase 2 meetings
- Type C: Any other product development topics not above
- Type D: Focused meeting on a narrow set of questions
Choosing the correct meeting type, and doing so at the optimal time, can influence development efficiency. For example, an INTERACT or Type B pre-IND meeting can save months by clarifying expectations before studies are initiated. Conversely, requesting a broad Type C meeting when a streamlined Type D would suffice may delay actionable feedback. Aligning your development stage with FDA’s meeting framework is essential for timely, targeted guidance.
2. Craft Focused, Answerable Questions
FDA meetings are most effective when sponsors ask specific, well-formulated questions. Broad or unfocused questions often lead to generalized responses that lack actionable direction. Effective question design includes:
- Prioritizing only the most critical issues and organizing questions based on their relevant category
- Framing questions to solicit clear yes or no responses
- Provide concise, relevant data and rationale to support the question
- Provide the right amount of supporting data with the question
Thoughtfully crafted questions demonstrate preparation, encourage meaningful dialogue, and help FDA provide feedback to support the development of your specific program.
3. Build a High-Quality Meeting Package
Your meeting package serves as the foundation for the Agency’s FDA’s review and feedback. A clear, concise, and well-organized package demonstrates credibility and enables reviewers to engage efficiently. Best practices include:
- Keeping narratives clear, well-structured, consistent, and succinct
- Using tables and figures to present data clearly
- Highlighting the information directly relevant to your questions
- Applying consistent formatting and logical flow throughout
- Ensure sufficient information is provided to the FDA so they can develop an informed response
A strong meeting package not only supports your questions but also enhances trust and rapport with FDA reviewers
4. Prepare the Team for In-Person or Virtual Meetings
Internal alignment is essential for polished and effective FDA interactions. Mixed messages, conflicting views, or uncertainty among team members can undermine credibility. Preparation tips include:
- Conducting mock rehearsals to ensure fluency and confidence.
- Aligning clear roles for who will lead each topic
- Aligning on ‘must-have’ vs. ‘nice-to-have’ outcomes
- Preparing for multiple potential FDA responses, including unfavorable ones
Team Tip: For a productive and collaborative meeting, be sure to:
- Open with a brief, high-level summary of your development program.
- Stick to the agenda; meeting time is limited
- Ask clarifying questions respectfully and avoid unnecessary debate
- Designate a primary note-taker so no details are missed. Thoughtful preparation ensures your team presents a unified, professional, and scientifically grounded front
5. Follow Up Diligently
What happens after the meeting is just as important as the discussion itself. Sponsors should:
- Carefully review FDA’s official meeting minutes or written responses
- Document internal interpretations and align on next steps
- Adjust development plans accordingly and communicate changes to stakeholders
If discrepancies or misunderstandings arise, address them promptly. Delays can introduce unnecessary risk into your program.
6. Leverage Experienced Regulatory Advisors
FDA meetings are more than regulatory checkpoints; they are opportunities to build a collaborative relationship with the Agency and to streamline your path to approval. Lumanity’s experienced regulatory consultants can guide you through all aspects of these interactions, including:
- Meeting request strategy and briefing package development
- Full meeting preparation and facilitation, including mock rehearsals and facilitation
- Post meeting interpretation and follow-up communication
Our team brings practical experience across a broad range of programs, deep familiarity with FDA’s communication style, and the strategic insight needed to frame questions that elicit meaningful, actionable feedback. We help anticipate Agency concerns and craft strategies to proactively address them.
Conclusion
Successful FDA meetings require deliberate strategy, rigorous preparation, and clear communication. With the right approach, and the right regulatory partners, these interactions can accelerate development, minimize risk, and clear the path to a more efficient regulatory approval, ultimately bringing innovative therapies to patients sooner. For early-stage companies, these engagements can serve as significant value-creating milestones in a program. In today’s increasingly competitive funding environment, using the right FDA meeting at the right time can streamline the path to the clinic and beyond.
Need a second set of eyes on your meeting strategy, meeting type selection, question framing, and briefing package structure? Lumanity can help you optimize your interaction with FDA and obtain clear, actionable feedback. Contact: contact@lumanity.com.
Jennifer Burke and Giovanni Ciavarra PhD
